NEW YORK (GenomeWeb) – Phoenix-based tumor profiling firm Paradigm Diagnostics has signed an exclusive distribution agreement with IDB Resources for Malaysia, Singapore, and Brunei.
Under the terms of the agreement, Malaysia-based IDB Resources will provide access to Paradigm's PCDx next-generation sequencing clinical tumor profiling service. The test offers information on potential therapies based on the characterization of the patient's tumor genome.
"We are excited to continue expansion of Paradigm's testing services outside the US," Paradigm President David Mallery said in a statement. "IDB Resources provides us with an experienced team to help realize growth in these markets over the short term."
IDB Resources is based in Petaling Jaya, Malaysia.
Financial and other terms of the agreement were not disclosed.